Shares in Black Diamond Therapeutics rose after the company outlined positive initial data from Phase 2 trials of BDTX-1535, an oral cancer treatment. Shares were up 46% in premarket trading at $6.94.
Elevation Oncology has won Food and Drug Administration fast-track designation for EO-3021, its lead drug candidate, in certain patients with gastrointestinal cancers.
Private equity's takeover of thousands of healthcare businesses has sparked a backlash among physicians, and many are joining new professional organizations to oppose corporate influence in U.S.